Clene Inc. to Showcase Neurodegenerative Disease Treatments at Canaccord 45th Annual Growth Conference

Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, is set to present at the Canaccord 45th Annual Growth Conference, showcasing its groundbreaking work in developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). The company's participation underscores the importance of its research in improving mitochondrial health and protecting neuronal function, offering hope to millions affected by these debilitating conditions.

The conference provides a platform for Clene to engage with investors and the broader scientific community, discussing its investigational therapy, CNM-Au8(R). This first-in-class treatment aims to enhance the survival and function of central nervous system cells by targeting mitochondrial function and the NAD pathway, while also reducing oxidative stress. For more details on Clene's presentation, visit https://ibn.fm/joSXx.

Clene's focus on neurodegenerative diseases comes at a critical time, as the global community seeks more effective treatments for conditions like ALS and MS, which currently have limited therapeutic options. The company's innovative approach could pave the way for new standards in care, offering patients improved quality of life and potentially slowing disease progression.

Investors and stakeholders interested in the latest developments from Clene can find additional information in the company's newsroom at https://ibn.fm/CLNN. Clene's participation in the Canaccord conference not only highlights its commitment to advancing neurodegenerative disease research but also positions the company as a key player in the biopharmaceutical industry's efforts to address some of the most challenging medical conditions today.